Literature DB >> 2602435

Characterisation of the first monoclonal antibody against the pronase resistant core of the Alzheimer PHF.

M Novak1, C M Wischik, P Edwards, R Pannell, C Milstein.   

Abstract

A monoclonal antibody, NOAL 6.423 has been produced which unequivocally identifies a protein which is a constituent of the pronase resistant core of the Alzheimer PHF. Although the site recognised by this antibody is contained somewhere within the highly conserved triple repeat region of the tau molecule, no experiments have succeeded so far in demonstrating NOAL 6.423 reactivity in any brain proteins other than those derived from PHFs. A site which can be recognised by NOAL 6.423 cannot be generated in preparations of normal porcine tau by simple proteolytic cleavage with pronase. Likewise reactivity with the PHF peptide recognised by NOAL 6.423 is not altered by alkaline phosphatase. The unusual properties of NOAL 6.423 are consistent with the possibility that its recognition site is not determined solely by the primary structure of the conserved region of the tau molecule.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2602435

Source DB:  PubMed          Journal:  Prog Clin Biol Res        ISSN: 0361-7742


  19 in total

1.  Cortical and hippocampal neurons from truncated tau transgenic rat express multiple markers of neurodegeneration.

Authors:  Peter Filipcik; Martin Cente; Gabriela Krajciova; Ivo Vanicky; Michal Novak
Journal:  Cell Mol Neurobiol       Date:  2009-03-05       Impact factor: 5.046

2.  Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies.

Authors:  David J Irwin; Todd J Cohen; Murray Grossman; Steven E Arnold; Sharon X Xie; Virginia M-Y Lee; John Q Trojanowski
Journal:  Brain       Date:  2012-03       Impact factor: 13.501

3.  Crystallization and preliminary X-ray diffraction analysis of two peptides from Alzheimer PHF in complex with the MN423 antibody Fab fragment.

Authors:  Rostislav Skrabana; Ondrej Cehlar; Zuzana Flachbartova; Andrej Kovac; Jozef Sevcik; Michal Novak
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2012-09-25

Review 4.  Intrinsically disordered proteins in the neurodegenerative processes: formation of tau protein paired helical filaments and their analysis.

Authors:  Rostislav Skrabana; Jozef Sevcik; Michal Novak
Journal:  Cell Mol Neurobiol       Date:  2006-06-16       Impact factor: 5.046

5.  Characterization of prefibrillar Tau oligomers in vitro and in Alzheimer disease.

Authors:  Kristina R Patterson; Christine Remmers; Yifan Fu; Sarah Brooker; Nicholas M Kanaan; Laurel Vana; Sarah Ward; Juan F Reyes; Keith Philibert; Marc J Glucksman; Lester I Binder
Journal:  J Biol Chem       Date:  2011-05-06       Impact factor: 5.157

6.  Difference between the tau protein of Alzheimer paired helical filament core and normal tau revealed by epitope analysis of monoclonal antibodies 423 and 7.51.

Authors:  M Novak; R Jakes; P C Edwards; C Milstein; C M Wischik
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-01       Impact factor: 11.205

7.  Tau Oligomer Pathology in Nucleus Basalis Neurons During the Progression of Alzheimer Disease.

Authors:  Chelsea T Tiernan; Elliott J Mufson; Nicholas M Kanaan; Scott E Counts
Journal:  J Neuropathol Exp Neurol       Date:  2018-03-01       Impact factor: 3.685

Review 8.  New age of neuroproteomics in Alzheimer's disease research.

Authors:  Branislav Kovacech; Norbert Zilka; Michal Novak
Journal:  Cell Mol Neurobiol       Date:  2009-02-19       Impact factor: 5.046

9.  Sequestration of tau by granulovacuolar degeneration in Alzheimer's disease.

Authors:  W Bondareff; C M Wischik; M Novak; M Roth
Journal:  Am J Pathol       Date:  1991-09       Impact factor: 4.307

10.  Detection of Alzheimer Disease (AD)-Specific Tau Pathology in AD and NonAD Tauopathies by Immunohistochemistry With Novel Conformation-Selective Tau Antibodies.

Authors:  Garrett S Gibbons; Rachel A Banks; Bumjin Kim; Lakshmi Changolkar; Dawn M Riddle; Susan N Leight; David J Irwin; John Q Trojanowski; Virginia M Y Lee
Journal:  J Neuropathol Exp Neurol       Date:  2018-03-01       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.